[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity
John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals (KNSA), exercised 29,325 share options at an exercise price of $3.80 and sold 29,325 Class A Ordinary Shares at a weighted average price of $32.55 under a Rule 10b5-1 trading plan. The filing states the option is fully vested and exercisable and reports post-transaction beneficial ownership figures of 86,728 and 57,403 Class A shares, plus 36,542 derivative securities. The sale was executed through a broker-dealer in multiple trades and the filer offers to provide trade-level price details on request.
John F. Paolini, Chief Medical Officer di Kiniksa Pharmaceuticals (KNSA), ha esercitato 29,325 opzioni su azioni al prezzo di esercizio di $3.80 e ha venduto 29,325 azioni ordinarie di Classe A a un prezzo medio ponderato di $32.55 nell'ambito di un piano di negoziazione ai sensi della Regola 10b5-1. La comunicazione specifica che l'opzione 猫 completamente maturata ed esercitabile e riporta, dopo l'operazione, una titolarit脿 beneficiaria di 86,728 e 57,403 azioni di Classe A, oltre a 36,542 strumenti derivati. La vendita 猫 stata eseguita tramite un broker-dealer in pi霉 operazioni; il dichiarante si rende disponibile a fornire i dettagli dei prezzi per singola operazione su richiesta.
John F. Paolini, director m茅dico de Kiniksa Pharmaceuticals (KNSA), ejerci贸 29,325 opciones sobre acciones a un precio de ejercicio de $3.80 y vendi贸 29,325 acciones ordinarias Clase A a un precio medio ponderado de $32.55 en el marco de un plan de negociaci贸n conforme a la norma 10b5-1. La presentaci贸n indica que la opci贸n est谩 totalmente consolidada y es ejercitable, y comunica, tras la transacci贸n, una titularidad beneficiaria de 86,728 y 57,403 acciones Clase A, adem谩s de 36,542 valores derivados. La venta se realiz贸 a trav茅s de un broker-dealer en varias operaciones; el declarante ofrece facilitar los precios por operaci贸n a petici贸n.
John F. Paolini電� Kiniksa Pharmaceuticals(KNSA)鞚� 斓滉碃鞚橂毂呾瀯鞛�(CMO)搿滌劀 頄夓偓臧�瓴� $3.80鞐� 29,325欤检潣 鞀ろ啞鞓奠厴鞚� 頄夓偓頃橁碃, 攴滌箼 10b5-1鞐� 霐半ジ 瓯半灅瓿勴殟鞐� 霐半澕 臧�欷戫弶攴� 臧�瓴� $32.55鞐� 29,325欤检潣 韥措灅鞀� A 氤错喌欤茧ゼ 毵る弰頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� 頃措嫻 鞓奠厴鞚� 鞕勳爠頌� 旆摑霅橃柎 頄夓偓 臧�電ロ晿雼り碃 氇呾嫓霅橃柎 鞛堨溂氅�, 瓯半灅 頉勳潣 鞁れ唽鞙� 歆�攵勳潃 韥措灅鞀� A 氤错喌欤� 86,728欤� 氚� 57,403欤检檧 36,542臧滌潣 韺岇儩歃濌秾鞙茧 氤搓碃霅橃柎 鞛堨姷雼堧嫟. 毵る弰電� 欷戧皽鞐呾瀽毳� 韱淀暣 鞐煬 彀鞚� 瓯半灅搿� 鞁ろ枆霅橃棃鞙茧┌, 鞝滌稖鞛愲姅 鞖旍箔 鞁� 臧滊硠 瓯半灅氤� 臧�瓴� 靹鸽秬雮挫棴鞚� 鞝滉车頃橁矤雼り碃 氚濏様鞀惦媹雼�.
John F. Paolini, directeur m茅dical (Chief Medical Officer) de Kiniksa Pharmaceuticals (KNSA), a exerc茅 29,325 options d'achat d'actions au prix d'exercice de $3.80 et a vendu 29,325 actions ordinaires de cat茅gorie A 脿 un prix moyen pond茅r茅 de $32.55 dans le cadre d'un plan de n茅gociation r茅gi par la r猫gle 10b5-1. Le d茅p么t indique que l'option est enti猫rement acquise et exer莽able et fait 茅tat, apr猫s la transaction, d'une d茅tention b茅n茅ficiaire de 86,728 et 57,403 actions de cat茅gorie A, ainsi que de 36,542 instruments d茅riv茅s. La vente a 茅t茅 r茅alis茅e par l'interm茅diaire d'un broker鈥慸ealer en plusieurs op茅rations ; le d茅clarant propose de communiquer les prix par transaction sur demande.
John F. Paolini, Chief Medical Officer von Kiniksa Pharmaceuticals (KNSA), hat 29,325 Aktienoptionen zum Aus眉bungspreis von $3.80 ausge眉bt und im Rahmen eines Rule鈥�10b5鈥�1鈥慔andelsplans 29,325 Class鈥慉鈥慡tammaktien zu einem gewichteten Durchschnittspreis von $32.55 verkauft. Die Meldung gibt an, dass die Option vollst盲ndig unverfallbar und aus眉bbar ist und berichtet nach der Transaktion 眉ber eine wirtschaftliche Beteiligung von 86,728 und 57,403 Class鈥慉鈥慉ktien sowie 36,542 derivativen Wertpapieren. Der Verkauf erfolgte 眉ber einen Broker鈥慏ealer in mehreren Trades; der Meldende bietet an, auf Anfrage handelsspezifische Preisdetails zur Verf眉gung zu stellen.
- Transaction executed under a Rule 10b5-1 plan, indicating a pre-established trading program
- Option is fully vested and exercisable, and the filer discloses willingness to provide detailed trade-level pricing
- Reported sale of 29,325 Class A Ordinary Shares, which reduces the reporting person鈥檚 beneficial ownership
- Post-transaction beneficial ownership figures include lower reported holdings (57,403 Class A shares) compared with pre-transaction totals
Insights
Routine option exercise and sale disclosed under a documented 10b5-1 plan; transparency is key for investors.
The filing shows an insider exercised 29,325 options at a low exercise price and sold the resulting shares at a materially higher weighted average price, producing potential cash proceeds. Because the transactions were processed under a Rule 10b5-1 plan and the option is confirmed fully vested, this appears to be a pre-planned, compliance-oriented disposition rather than an opportunistic market-timing sale. The filer鈥檚 offer to provide per-trade pricing supports transparency. Impact to outstanding float appears limited given the reported post-transaction ownership figures.
Disclosure follows standard governance practices; documented plan and attorney-in-fact signature improve procedural clarity.
The Form 4 documents execution under a written 10b5-1 plan and includes an attorney-in-fact signature, which addresses procedural governance and insider-trading compliance considerations. The filing also discloses option vesting status and post-transaction ownership counts, enabling shareholders to assess insider alignment with company performance. While insider sales can raise investor questions, the presence of a pre-existing plan and explicit trade pricing information reduces ambiguity about intent.
John F. Paolini, Chief Medical Officer di Kiniksa Pharmaceuticals (KNSA), ha esercitato 29,325 opzioni su azioni al prezzo di esercizio di $3.80 e ha venduto 29,325 azioni ordinarie di Classe A a un prezzo medio ponderato di $32.55 nell'ambito di un piano di negoziazione ai sensi della Regola 10b5-1. La comunicazione specifica che l'opzione 猫 completamente maturata ed esercitabile e riporta, dopo l'operazione, una titolarit脿 beneficiaria di 86,728 e 57,403 azioni di Classe A, oltre a 36,542 strumenti derivati. La vendita 猫 stata eseguita tramite un broker-dealer in pi霉 operazioni; il dichiarante si rende disponibile a fornire i dettagli dei prezzi per singola operazione su richiesta.
John F. Paolini, director m茅dico de Kiniksa Pharmaceuticals (KNSA), ejerci贸 29,325 opciones sobre acciones a un precio de ejercicio de $3.80 y vendi贸 29,325 acciones ordinarias Clase A a un precio medio ponderado de $32.55 en el marco de un plan de negociaci贸n conforme a la norma 10b5-1. La presentaci贸n indica que la opci贸n est谩 totalmente consolidada y es ejercitable, y comunica, tras la transacci贸n, una titularidad beneficiaria de 86,728 y 57,403 acciones Clase A, adem谩s de 36,542 valores derivados. La venta se realiz贸 a trav茅s de un broker-dealer en varias operaciones; el declarante ofrece facilitar los precios por operaci贸n a petici贸n.
John F. Paolini電� Kiniksa Pharmaceuticals(KNSA)鞚� 斓滉碃鞚橂毂呾瀯鞛�(CMO)搿滌劀 頄夓偓臧�瓴� $3.80鞐� 29,325欤检潣 鞀ろ啞鞓奠厴鞚� 頄夓偓頃橁碃, 攴滌箼 10b5-1鞐� 霐半ジ 瓯半灅瓿勴殟鞐� 霐半澕 臧�欷戫弶攴� 臧�瓴� $32.55鞐� 29,325欤检潣 韥措灅鞀� A 氤错喌欤茧ゼ 毵る弰頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� 頃措嫻 鞓奠厴鞚� 鞕勳爠頌� 旆摑霅橃柎 頄夓偓 臧�電ロ晿雼り碃 氇呾嫓霅橃柎 鞛堨溂氅�, 瓯半灅 頉勳潣 鞁れ唽鞙� 歆�攵勳潃 韥措灅鞀� A 氤错喌欤� 86,728欤� 氚� 57,403欤检檧 36,542臧滌潣 韺岇儩歃濌秾鞙茧 氤搓碃霅橃柎 鞛堨姷雼堧嫟. 毵る弰電� 欷戧皽鞐呾瀽毳� 韱淀暣 鞐煬 彀鞚� 瓯半灅搿� 鞁ろ枆霅橃棃鞙茧┌, 鞝滌稖鞛愲姅 鞖旍箔 鞁� 臧滊硠 瓯半灅氤� 臧�瓴� 靹鸽秬雮挫棴鞚� 鞝滉车頃橁矤雼り碃 氚濏様鞀惦媹雼�.
John F. Paolini, directeur m茅dical (Chief Medical Officer) de Kiniksa Pharmaceuticals (KNSA), a exerc茅 29,325 options d'achat d'actions au prix d'exercice de $3.80 et a vendu 29,325 actions ordinaires de cat茅gorie A 脿 un prix moyen pond茅r茅 de $32.55 dans le cadre d'un plan de n茅gociation r茅gi par la r猫gle 10b5-1. Le d茅p么t indique que l'option est enti猫rement acquise et exer莽able et fait 茅tat, apr猫s la transaction, d'une d茅tention b茅n茅ficiaire de 86,728 et 57,403 actions de cat茅gorie A, ainsi que de 36,542 instruments d茅riv茅s. La vente a 茅t茅 r茅alis茅e par l'interm茅diaire d'un broker鈥慸ealer en plusieurs op茅rations ; le d茅clarant propose de communiquer les prix par transaction sur demande.
John F. Paolini, Chief Medical Officer von Kiniksa Pharmaceuticals (KNSA), hat 29,325 Aktienoptionen zum Aus眉bungspreis von $3.80 ausge眉bt und im Rahmen eines Rule鈥�10b5鈥�1鈥慔andelsplans 29,325 Class鈥慉鈥慡tammaktien zu einem gewichteten Durchschnittspreis von $32.55 verkauft. Die Meldung gibt an, dass die Option vollst盲ndig unverfallbar und aus眉bbar ist und berichtet nach der Transaktion 眉ber eine wirtschaftliche Beteiligung von 86,728 und 57,403 Class鈥慉鈥慉ktien sowie 36,542 derivativen Wertpapieren. Der Verkauf erfolgte 眉ber einen Broker鈥慏ealer in mehreren Trades; der Meldende bietet an, auf Anfrage handelsspezifische Preisdetails zur Verf眉gung zu stellen.
FAQ
Who filed the Form 4 for Kiniksa (KNSA)?
What transactions did the insider report on the Form 4 for KNSA?
Were these trades executed under a trading plan for KNSA insider activity?
What post-transaction ownership figures are reported for KNSA?
At what price were the sold shares executed for KNSA?
Is there confirmation the option exercised by the KNSA insider was vested?
